Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 2:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 116 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Deep Vein Thrombosis, Pulmonary Embolus Clear all
Completed Phase 3 Interventional Results available

Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study

NCT00439725
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
1,197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
25
States / cities
Little Rock, Arkansas • Los Angeles, California • Redlands, California + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2014 · Synced Oct 4, 2026, 2:50 PM EDT
Completed Not applicable Interventional

Single Comprehensive Ultrasound to Rule Out DVT in High-risk Patients

NCT00333697
View directory record Official record
Conditions
Deep Vein Thrombosis
Interventions
Comprehensive Duplex Ultrasound (diagnostic study)
Other
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
2
States / cities
Murray, Utah • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 21, 2011 · Synced Oct 4, 2026, 2:50 PM EDT
Completed Phase 3 Interventional Results available

Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3)

NCT00423319
View directory record Official record
Conditions
Deep Vein Thrombosis, Pulmonary Embolism
Interventions
Enoxaparin, Apixaban, Enoxaparin-matching placebo, Apixaban-matching placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
5,407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
19
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Sacramento, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 14, 2014 · Synced Oct 4, 2026, 2:50 PM EDT
Completed Phase 3 Interventional Results available

Cancer Venous Thromboembolism (VTE)

NCT02073682
View directory record Official record
Conditions
Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Cancer
Interventions
Edoxaban, Dalteparin, Low molecular weight heparin
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
1,046 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
4
States / cities
Brandon, Florida • Jonesboro, Georgia • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2019 · Synced Oct 4, 2026, 2:50 PM EDT
Completed Phase 3 Interventional

SR34006 Compared to Placebo in Patients Who Have Completed 6 Months of Treatment for Symptomatic Pulmonary Embolism or Deep Vein Thrombosis

NCT00071279
View directory record Official record
Conditions
Pulmonary Embolism, Deep Vein Thrombosis
Interventions
SR34006 (idraparinux sodium) Injection
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
1,215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
32
States / cities
Bay Pines, Florida • Brandon, Florida • Jacksonville, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2011 · Synced Oct 4, 2026, 2:50 PM EDT
Completed No phase listed Observational

Systematic Assessment and Targeted Improvement of Services Following Yearlong Surgical Outcomes Surveys

NCT02032030
View directory record Official record
Conditions
Heart Attack, Cardiac Arrest, Congestive Heart Failure, Atrial Fibrillation, Angina, Deep Vein Thrombosis, Pulmonary Embolism, Respiratory Arrest, Respiratory Failure, Pneumonia, Gastrointestinal Bleed, Stomach Ulcer, Delirium, Stroke, Nerve Injury, Surgical Wound Infection
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
73,952 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 9, 2022 · Synced Oct 4, 2026, 2:50 PM EDT
Completed Not applicable Interventional Results available

The Angel® Catheter Pivotal Clinical Trial

NCT02186223
View directory record Official record
Conditions
Pulmonary Embolism, Deep Vein Thrombosis, Venous Thromboembolism, Trauma
Interventions
The Angel® Catheter
Device
Lead sponsor
BiO2 Medical
Industry
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
21
States / cities
Los Angeles, California • San Diego, California • Loveland, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 4, 2026, 2:50 PM EDT
Completed Early Phase 1 Interventional

Real-time Anti-Factor Xa Measurements in Surgical Patients to Examine Enoxaparin Metabolism and Optimize Enoxaparin Dose

NCT02704052
View directory record Official record
Conditions
Deep Venous Thrombosis, Pulmonary Embolus, Venous Thromboembolism
Interventions
Real time enoxaparin dose adjustment, Standard enoxaparin dose
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 24, 2019 · Synced Oct 4, 2026, 2:50 PM EDT
Completed Not applicable Interventional Results available

A Prospective, Multi-Center Study of the Bard® Denali™ Retrievable Inferior Vena Cava Filter System

NCT01305564
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Denali inferior vena cava filter
Device
Lead sponsor
C. R. Bard
Industry
Eligibility
21 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
22
States / cities
Birmingham, Alabama • Phoenix, Arizona • Hartford, Connecticut + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2016 · Synced Oct 4, 2026, 2:50 PM EDT
Completed Phase 3 Interventional

Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients

NCT00135876
View directory record Official record
Conditions
Venous Thromboembolism, Brain Tumors
Interventions
dalteparin
Drug
Lead sponsor
Ontario Clinical Oncology Group (OCOG)
Other
Eligibility
18 Years and older
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
3
States / cities
Evanston, Illinois • Detroit, Michigan • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 27, 2007 · Synced Oct 4, 2026, 2:50 PM EDT
Active, not recruiting Phase 4 Interventional

Therapeutic Initial Heparin Dosing for Patients With Clots or Certain Heart Conditions Admitted to the Hospital

NCT07250763
View directory record Official record
Conditions
Pulmonary Embolism, Deep Vein Thrombosis, Atrial Fibrillation, Acute Cardiac Syndrome, Mechanical Heart Valve Recipients
Interventions
Initial Heparin Dose Modification
Drug
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Alexandria, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 4, 2026, 2:50 PM EDT
Terminated Not applicable Interventional Results available

Evaluation of the Technical Success of IVUS Guided VCF Placement Using the LUMIFI™ With Crux® VCF System

NCT02394912
View directory record Official record
Conditions
Pulmonary Embolism, Deep Vein Thrombosis
Interventions
vena cava filter implantation (LUMIFI with Crux VCF System)
Device
Lead sponsor
Volcano Corporation
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Louisville, Kentucky • Orangeburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Oct 4, 2026, 2:50 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bedside Ultrasound in the Assessment of Deep Venous Thrombosis: Effectiveness of In-Person Versus Online Instruction

NCT03573492
View directory record Official record
Conditions
Deep Vein Thrombosis, Pulmonary Embolism
Interventions
Education
Other
Lead sponsor
Mercy Health Ohio
Other
Eligibility
Not listed
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Youngstown, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 1, 2019 · Synced Oct 4, 2026, 2:50 PM EDT
Completed Phase 2Phase 3 Interventional Results available

The Use of Fondaparinux in Preventing Thromboembolism in High Risk Trauma Patients

NCT00531843
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
fondaparinux sodium, sequential compression devices
Drug · Device
Lead sponsor
Mary Knudson, M.D.
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 24, 2013 · Synced Oct 4, 2026, 2:50 PM EDT
Completed Phase 3 Interventional Results available

Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)

NCT02798471
View directory record Official record
Conditions
Venous Thromboembolism (VTE), Pulmonary Embolism, Deep Vein Thrombosis (DVT)
Interventions
Edoxaban, Standard of Care
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
1 Day to 17 Years
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
22
States / cities
Tucson, Arizona • Los Angeles, California • Stanford, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2025 · Synced Oct 4, 2026, 2:50 PM EDT
Completed Phase 2 Interventional

Evaluation of PD 0348292 for Preventing Blood Clots in the Lungs or Deep Leg Veins of Patients After Knee Surgery

NCT00306254
View directory record Official record
Conditions
Venous Thrombosis
Interventions
PD 0348292, Enoxaparin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
58
States / cities
Birmingham, Alabama • Little Rock, Arkansas • North Little Rock, Arkansas + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2007 · Synced Oct 4, 2026, 2:50 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Evaluation of Implementation of a National Point-of-Care Ultrasound Training Program

NCT03296280
View directory record Official record
Conditions
Other Acute Illnesses Presenting to the Hospital, Heart Failure, Pneumonia, Deep Venous Thrombosis, Cellulitis, Abdominal Aortic Aneurysm, Acute Cholecystitis, Peritoneal Free Fluid, Hydronephrosis, Pleural Effusion, Urinary Retention
Interventions
Not listed
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Not listed
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 4, 2026, 2:50 PM EDT
Completed No phase listed Observational

Multi-Center Human Alert Trial to Prevent DVT and PE

NCT00409136
View directory record Official record
Conditions
Pulmonary Embolism, Deep Vein Thrombosis, Cancer, Surgery
Interventions
Human Alert
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
2,496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
26
States / cities
Scottsdale, Arizona • Long Beach, California • Orange, California + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2009 · Synced Oct 4, 2026, 2:50 PM EDT
Completed Phase 3 Interventional Results available

Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement.

NCT00362232
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin, Placebo: tablet of Rivaroxaban, Placebo: syringes of Enoxaparin
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
3,148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
40
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2014 · Synced Oct 4, 2026, 2:50 PM EDT
Completed Not applicable Interventional

Improving Safety of Diagnosis and Therapy in the Inpatient Setting

NCT04393909
View directory record Official record
Conditions
Delirium, Confusion, Mental Status Change, Back Pain, Hip Pain Chronic, Chest Pain, Asthma, COPD, Cellulitis, Soft Tissue Infections, Cough, Deep Vein Thrombosis, Pulmonary Embolism, Venous Thromboembolism, Dyspnea, Electrolyte Metabolism Abnormal, Fever, Failure to Thrive, Weakness, Protein-Calorie Malnutrition, Headache, Neck Pain, Hypoxia, Pneumonia, Sepsis, Syncope, Vomiting, Diarrhea, Leg Pain, Abdominal Pain
Interventions
Diagnostic Uncertainty Educational Curriculum, Diagnostic Timeout, Patient Diagnostic (Dx) Questionnaire, Enhancements to Epic-integrated Quality & Safety Dashboard
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Oct 4, 2026, 2:50 PM EDT
Completed Not applicable Interventional Results available

Thrombelastography Based Dosing of Enoxaparin

NCT00990236
View directory record Official record
Conditions
Thromboembolic Complications
Interventions
Enoxaparin dose adjusted Lovenox based on TEG, Enoxaparin 30 mg BID
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
15 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
3
States / cities
Portland, Oregon • Houston, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 3, 2020 · Synced Oct 4, 2026, 2:50 PM EDT
Completed No phase listed Observational

Emulation of the RECORD3 Trial Using Healthcare Claims Data

NCT07599384
View directory record Official record
Conditions
Deep Vein Thrombosis, Pulmonary Embolus
Interventions
Rivaroxaban, Enoxaparin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
149,248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 4, 2026, 2:50 PM EDT
Completed No phase listed Observational

Epidemiology of Venous Thromboembolism

NCT00456196
View directory record Official record
Conditions
Venous Thromboembolism, Pulmonary Embolism, Cancer, Deep Vein Thrombosis, COPD
Interventions
Not listed
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
Not listed
Enrollment
5,451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 13, 2009 · Synced Oct 4, 2026, 2:50 PM EDT
Completed Phase 4 Interventional Results available

Venous Thromboembolic Prophylaxis After Trauma: Three Times a Day Unfractionated Heparin Versus Twice a Day Enoxaparin

NCT01729559
View directory record Official record
Conditions
Venous Thromboembolic Disease, Deep Vein Thrombosis, Pulmonary Embolism
Interventions
5000 Units unfractionated Heparin Q 8 hr, 30mg enoxaparin Q12 hr
Drug
Lead sponsor
Scripps Health
Other
Eligibility
18 Years and older
Enrollment
495 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 18, 2016 · Synced Oct 4, 2026, 2:50 PM EDT